- Home
- TRVI vs VCYT Comparison
TRVI vs VCYT Comparison
Compare TRVI & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRVI | VCYT |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TRVI | VCYT |
|---|---|---|
| Price | $17.14 | $57.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $21.55 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.91 | ★ 164.52 |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.76 |
| Revenue Next Year | N/A | $12.35 |
| P/E Ratio | ★ N/A | $165.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.55 | $22.92 |
| 52 Week High | $20.22 | $60.91 |
Technical Indicators
Market Signals| Indicator | TRVI | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 58.26 |
| Support Level | $16.24 | $40.27 |
| Resistance Level | $20.15 | $60.86 |
| Average True Range (ATR) | 1.37 | 2.77 |
| MACD | -0.23 | -0.44 |
| Stochastic Oscillator | 22.61 | 71.54 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).